iproniazid has been researched along with Methemoglobinemia in 1 studies
Methemoglobinemia: The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait). (Dorland, 27th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, RP | 1 |
| Alkaitis, AA | 1 |
| Shafer, PR | 1 |
1 other study available for iproniazid and Methemoglobinemia
| Article | Year |
|---|---|
Chemically induced methemoglobinemias in the mouse.
Topics: Acetophenones; Aniline Compounds; Animals; Arginine; Azides; Erythrocytes; Female; Hydroxylamines; I | 1967 |